Gensci-134 (Genescience Pharmaceuticals Co. Ltd.) is a growth hormone receptor (GHR) agonist fusion protein that mimics the biological activity of growth hormone (GH), does not contain GH sequence and ...

Ethyreal will share more information on its asset at the Endocrine Society’s 2026 Annual Meeting. (iStock/Getty Images Plus) Ethyreal Bio has exited stealth with $101 million in funding, joining the ...

Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder characterized by dysregulation in humoral immunity and sustained activation of B cells and autoantibody release, where BAFF (B-cell ...

TASHKENT, UZBEKISTAN - June 7, 2026 (NEWMEDIAWIRE) - A business delegation led by the Chief Executive of the Hong Kong Special Administrative Region (HKSAR), John Lee, and organised by the Hong Kong ...

The rheumatoid arthritis clinical trial analysis report delivers important insights into ongoing research of 80+ pipeline rheumatoid arthritis drugs, clinical strategies, upcoming therapeutics, and ...

DelveInsight's “Endometriosis Pipeline Insight 2025” report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Endometriosis pipeline landscape. It covers the Endometriosis ...

Endometriosis is a prevalent yet underdiagnosed disease affecting a large population of women of reproductive age, with a substantial and lasting impact on quality of life and fertility. While rising ...

Shanghai Scizeng Medical Technology Co Ltd - a subsidiary of Changchun GeneScience Pharmaceutical Co Ltd (GenSci), RTW Investments, a New York-based global full life-cycle investment firm and Yarrow ...

Yarrow Bioscience, financially backed by founder RTW Investments, will pay $70 million upfront for ex-China rights to a potentially first-in-class TSHR antibody drug. (Pro2sound/iStock/Getty Images ...

Collaboration to focus on building a leading, US-based biotech dedicated to addressing underserved patients impacted by autoimmune and endocrinology disorders GenSci to receive $70 million ...

Denmark’s ALK-Abelló (OMX: ALK B) has entered into a partnership agreement with China-based Changchun GeneScience Pharmaceutical (GenSci) to develop and commercialize ALK’s house dust mite (HDM) ...

ALK (ALKB:DC / OMX: ALK B) today announced a partnership agreement with China-based Changchun GeneScience Pharmaceutical Co. Ltd. (“GenSci”) to develop and commercialise ALK’s house dust mite (“HDM”) ...